Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,033 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clotting Disorder Clear all
Completed Phase 2 Interventional

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

NCT00005652
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
rituximab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 24, 2026, 8:42 PM EDT
Recruiting No phase listed Observational

Von Willebrand Factor in Pregnancy (VIP) Study

NCT04146376
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Use of a postpartum diary and additional blood draws., VWF replacement therapy with Wilate, Tranexamic acid
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational

Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia a Monitoring

NCT06369740
View directory record Official record
Conditions
Hemophilia a
Interventions
Case scenarios - questionnaire, Case scenarios - Focus groups, Use scenarios - Usability test, Use scenarios - interview
Other
Lead sponsor
Enzyre B.V.
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

NCT01444417
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
Interventions
Romiplostim, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 24, 2026, 8:42 PM EDT
Terminated No phase listed Observational

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

NCT04904276
View directory record Official record
Conditions
ITP, Immune Thrombocytopenia
Interventions
Fostamatinib
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 24, 2026, 8:42 PM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

NCT00902018
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Eltrombopag, Romiplostim, healthy controls
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 24, 2026, 8:42 PM EDT
Terminated Phase 1 Interventional Results available

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

NCT02009761
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
BI 655064
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

NCT01476423
View directory record Official record
Conditions
Congenital Bleeding Disorder, Glanzmann's Disease
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 24, 2026, 8:42 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

NCT05181618
View directory record Official record
Conditions
Severe Hemophilia A, Moderate Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 69 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Miami, Florida • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

NCT02615691
View directory record Official record
Conditions
Hemophilia A
Interventions
PEGylated Recombinant Factor VIII, ITI
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 24, 2026, 8:42 PM EDT
Withdrawn No phase listed Observational

An Observational Study of Early Coagulopathy, or Clotting Disorder, in Injured Patients

NCT00744003
View directory record Official record
Conditions
Trauma-induced Coagulopathy
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Study To Assess The Safety, Parameters And Efficacy For Procedures Using A Radiofrequency Device

NCT05166824
View directory record Official record
Conditions
Tissue Heating, Coagulation
Interventions
TempSure, Scalpel, Bovie, Pelleve
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
5
States / cities
Westford, Massachusetts • Portsmouth, New Hampshire • Montclair, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational

Use of ROTEM for Multi-level Spine Surgery

NCT00839995
View directory record Official record
Conditions
Coagulation
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational

Thromboelastogram in Postdelivery Preeclamptic Patients

NCT03555630
View directory record Official record
Conditions
Preeclampsia, Coagulation Disorder, Pregnancy Complications
Interventions
Thromboelastogram
Diagnostic Test
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 24, 2026, 8:42 PM EDT
Not listed Phase 1Phase 2 Interventional

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

NCT04833764
View directory record Official record
Conditions
Post-thrombotic Syndrome, Deep Vein Thrombosis Leg
Interventions
Rosuvastatin
Drug
Lead sponsor
Khanh Nguyen
Federal
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 8:42 PM EDT
Terminated Not applicable Interventional

nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF

NCT00950092
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Numeris-AF Tethered Coagulation System with VisiTrax
Device
Lead sponsor
nContact Surgical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Venice, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

NCT00885742
View directory record Official record
Conditions
Factor XIII Deficiency
Interventions
FXIII Concentrate (Human)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Dothan, Alabama • Oakland, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thromboelastography to Assess Age-Related Coagulation Differences in Patients Undergoing Cesarean Delivery

NCT01416454
View directory record Official record
Conditions
Thrombophilia
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Not applicable Interventional

Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia

NCT03842605
View directory record Official record
Conditions
Hemophilia, Elbow Joint Contracture
Interventions
Strength training
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 24, 2026, 8:42 PM EDT
Completed Phase 2 Interventional

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

NCT00005797
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 24, 2026, 8:42 PM EDT
Completed No phase listed Observational

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

NCT00433862
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils, Chronic Myeloproliferative Disorders
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 8:42 PM EDT
Recruiting Phase 3 Interventional

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Year to 74 Years · Male only
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Iowa City, Iowa • New Hyde Park, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 8:42 PM EDT